US Supreme Court declines ex-InterMune CEO appeal
This article was originally published in Scrip
The US Supreme Court on 16 December declined to hear an appeal from Dr Scott Harkonen, the former CEO of InterMune, who was convicted in September 2009 of wire fraud for his role in creating and disseminating an August 2002 press release deemed by federal prosecutors as containing "fraudulent" statements about Actimmune (Interferon gamma-1b), the company's bioengineered form of interferon gamma, a protein that acts as a biologic response modifier through stimulation of the human immune system.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.